PYPD
Price
$6.53Alerts
Change
-$0.01 (-0.15%)
Updated
Nov 18, 04:59 PM (EDT)
Capitalization
124.71M
84 days until earnings call
Intraday BUY SELL Signals
SYRE
Price
$101.46Alerts
Change
+$7.65 (+8.15%)
Updated
Nov 18 closing price
Capitalization
9.16B
106 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PYPD vs SYRE

PYPD vs SYRE Comparison Chart in %
View a ticker or compare two or three
VS
PYPD vs. SYRE commentary
Nov 19, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PYPD is a Buy and SYRE is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for PYPD with price predictions
Nov 17, 2026

Aroon Indicator for PYPD shows an upward move is likely

PYPD's Aroon Indicator triggered a bullish signal on November 17, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 115 similar instances where the Aroon Indicator showed a similar pattern. In 103 of the 115 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on PYPD as a result. In 113 of 128 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.

The Moving Average Convergence Divergence (MACD) for PYPD just turned positive on October 22, 2026. Looking at past instances where PYPD's MACD turned positive, the stock continued to rise in 44 of 50 cases over the following month. The odds of a continued upward trend are 88%.

PYPD moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PYPD crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.

Following a +5.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where PYPD advanced for three days, in 179 of 218 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The 10-day RSI Indicator for PYPD moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator moved out of overbought territory. In 16 of the 18 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 49 cases where PYPD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PYPD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

PYPD broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PYPD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (23.147) is normal, around the industry mean (3.592). P/E Ratio (-4.687) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PYPD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for SYRE with price predictions
Nov 17, 2026

SYRE sees MACD Histogram just turned negative

SYRE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 17, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 39 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for SYRE moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 23 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 59 cases where SYRE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SYRE as a result. In 62 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

SYRE broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

SYRE moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SYRE crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.

Following a +12.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 261 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

The Aroon Indicator entered an Uptrend today. In 148 of 174 cases where SYRE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.592) is normal, around the industry mean (3.592). P/E Ratio (-54.111) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
PYPD vs SYRE: Fundamental Ratings
PYPD
SYRE
OUTLOOK RATING
1..100
3088
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
3534
P/E GROWTH RATING
1..100
7357
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SYRE's Valuation (4) in the Pharmaceuticals Major industry is significantly better than the same rating for PYPD (86) in the null industry. This means that SYRE’s stock grew significantly faster than PYPD’s over the last 12 months.

SYRE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PYPD (100) in the null industry. This means that SYRE’s stock grew similarly to PYPD’s over the last 12 months.

SYRE's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as PYPD (100) in the null industry. This means that SYRE’s stock grew similarly to PYPD’s over the last 12 months.

SYRE's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as PYPD (35) in the null industry. This means that SYRE’s stock grew similarly to PYPD’s over the last 12 months.

SYRE's P/E Growth Rating (57) in the Pharmaceuticals Major industry is in the same range as PYPD (73) in the null industry. This means that SYRE’s stock grew similarly to PYPD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PYPDSYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 8 days ago
82%
Bullish Trend 10 days ago
87%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
COMPARISON
Comparison
Nov 19, 2026
Stock price -- (PYPD: $6.54 vs. SYRE: $93.81)
Brand notoriety: PYPD and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PYPD: 662% vs. SYRE: 83%
Market capitalization -- PYPD: $124.71M vs. SYRE: $9.16B
PYPD [@Biotechnology] is valued at $124.71M. SYRE’s [@Biotechnology] market capitalization is $9.16B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PYPD’s FA Score shows that 0 FA rating(s) are green while SYRE’s FA Score has 1 green FA rating(s).

  • PYPD’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 1 green, 4 red.
According to our system of comparison, SYRE is a better buy in the long-term than PYPD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PYPD’s TA Score shows that 6 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • PYPD’s TA Score: 6 bullish, 4 bearish.
  • SYRE’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, PYPD is a better buy in the short-term than SYRE.

Price Growth

PYPD (@Biotechnology) experienced а +3.65% price change this week, while SYRE (@Biotechnology) price change was -10.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.10%. For the same industry, the average monthly price growth was -10.38%, and the average quarterly price growth was -24.10%.

Reported Earning Dates

PYPD is expected to report earnings on Feb 10, 2027.

SYRE is expected to report earnings on Mar 04, 2027.

Industries' Descriptions

@Biotechnology (-11.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

PYPD and

Correlation & Price change

A.I.dvisor tells us that PYPD and BCYC have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PYPD and BCYC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PYPD
1D Price
Change %
PYPD100%
+6.34%
BCYC - PYPD
31%
Poorly correlated
+0.63%
TSHA - PYPD
31%
Poorly correlated
-1.48%
IDYA - PYPD
29%
Poorly correlated
-9.75%
AMLX - PYPD
29%
Poorly correlated
-1.01%
SYRE - PYPD
29%
Poorly correlated
-5.60%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LABX4.340.36
+9.05%
Tradr 2X Long ALAB Daily ETF (LABX)
AMKL2.430.01
+0.41%
Defiance Daily Target 2X Long AMKR ETF (AMKL)
IBMS25.44-0.09
-0.37%
iShares iBonds Dec 2030 Term Muni Bond ETF (IBMS)
MKOR47.12-0.43
-0.90%
Matthews Korea Active ETF (MKOR)
IDEQ32.48-0.38
-1.16%
Lazard Active ETF TR